Pelthos Therapeutics Inc.
No trades
No trades
Compare with Pelthos Therapeutics Inc.
−26.36 USD
−43.32 M USD
16.80 M USD
1.54 M
Last report date
Aug 13, 2026
Report period
Q2 2026
EPS
−6.62 USD
Revenue
15.60 M USD
Earnings call summary
Q2 2026 saw strong revenue growth and prescription gains for ZELSUVMI, supported by expanded PBM access and increased prescriber adoption. Net product revenue rose 45% sequentially, with robust cash reserves and preparations underway for XEPI and XEGLYZE launches in 2027.
Details
Sector
Industry
CEO
Scott M. Plesha
Website
Headquarters
Durham
Founded
2021
ISIN
US1711262048
CUSIP
171126204
FIGI
BBG01C9YP5V5
Identifiers
ISIN US1711262048
Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. It produces products under its proprietary nitic oxide-based technology platform "Nitricil". Its main product is a topical gel for the treatment of molluscum contagiosum. The company was founded on March 19, 2021 and is headquartered in Durham, NC.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
The current price of PTHS is 27.50 USD — it has decreased by −3.14% in the past 24 hours. Watch Pelthos Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Pelthos Therapeutics Inc. stocks are traded under the ticker PTHS.
PTHS stock has fallen by −4.33% compared to the previous week, the month change is a 11.31% rise, over the last year Pelthos Therapeutics Inc. has showed a 47.93% increase.
We've gathered analysts' opinions on Pelthos Therapeutics Inc. future price: according to them, PTHS price has a max estimate of 64.00 USD and a min estimate of 45.00 USD. Watch PTHS chart and read a more detailed Pelthos Therapeutics Inc. stock forecast: see what analysts think of Pelthos Therapeutics Inc. and suggest that you do with its stocks.
PTHS reached its all-time high on Feb 16, 2024 with the price of 600.00 USD, and its all-time low was 12.30 USD and was reached on Jul 1, 2025. View more price dynamics on PTHS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PTHS stock is 7.34% volatile and has beta coefficient of 1.75. Track Pelthos Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Pelthos Therapeutics Inc. there?
Today Pelthos Therapeutics Inc. has the market capitalization of 100.62 M, it has increased by 4.91% over the last week.
Yes, you can track Pelthos Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Pelthos Therapeutics Inc. is going to release the next earnings report on Nov 12, 2026. Keep track of upcoming events with our Earnings Calendar.
PTHS earnings for the last quarter are −6.62 USD per share, whereas the estimation was −2.82 USD resulting in a −134.87% surprise. The estimated earnings for the next quarter are −2.90 USD per share. See more details about Pelthos Therapeutics Inc. earnings.
Pelthos Therapeutics Inc. revenue for the last quarter amounts to 15.60 M USD, despite the estimated figure of 15.17 M USD. In the next quarter, revenue is expected to reach 17.97 M USD.
PTHS net income for the last quarter is −23.42 M USD, while the quarter before that showed −25.07 M USD of net income which accounts for 0.00% change. Track more Pelthos Therapeutics Inc. financial stats to get the full picture.
No, PTHS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 14, 2026, the company has 92 employees. See our rating of the largest employees — is Pelthos Therapeutics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Pelthos Therapeutics Inc. EBITDA is −52.46 M USD, and current EBITDA margin is −179.05%. See more stats in Pelthos Therapeutics Inc. financial statements.
Like other stocks, PTHS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Pelthos Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Pelthos Therapeutics Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Pelthos Therapeutics Inc. stock shows the sell signal. See more of Pelthos Therapeutics Inc. technicals for a more comprehensive analysis.